13 Oct 2008 07:00
Immunodiagnostic Systems Holdings plc
Pre - Close Trading Update
Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, is pleased to announce that turnover for the first six months of this year is in line with management expectations. Sales are up 84.5% compared to the same period last year and on a pro-forma basis the comparative is 21%. The continued growth in the business reflects the increasing clinical recognition of the value of Vitamin D not only as a marker of bone disease but also its value as a marker of general well-being.
The development of assays for the IDSiSYS, previously referred to as the 3x3, continues apace and we anticipate the first commercial shipments of both the IDSiSYS instrument and the Company's flagship Vitamin D product to commence in January 2009.
Discussions with regard to the disposal of the Company's haematology business continue to advance and the market will be updated when appropriate.
Trading continues to be in line with expectations and the Board remains confident for the financial year as a whole to 31 March 2009.
IDS will announce Interim Results for the six months ended 30 September 2008 during December 2008.
For further information:
| Immunodiagnostic Systems Holdings plc | Tel: 0191 519 0660 |
| Roger Duggan, Chief Executive Officer | |
| Paul Hailes, Finance Director | |
| Oriel Securities Limited | Tel: 020 7710 7600 |
| (Nominated Adviser and Broker) | |
| Andrew Edwards, Gareth Price, James Nevin | |
| Parkgreen Communications Limited | Tel: 020 7933 8787 |
| Paul McManus | Mob: 07980 541 893 |
| paul.mcmanus@parkgreenmedia.com | |
| Ben Knowles | Mob: 07900 346 978 |
| Ben.knowles@parkgreenmedia.com |